- Latest available (Revised)
- Point in Time (18/10/2005)
- Original (As adopted by EU)
Council Regulation (EEC) No 2377/90 (repealed)Show full title
Council Regulation (EEC) No 2377/90 of 26 June 1990 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (repealed)
You are here:
What Version
Advanced Features
- Show Geographical Extent(e.g. England, Wales, Scotland and Northern Ireland)
- Show Timeline of Changes
More Resources
Revised version PDFs
- Revised 02/09/20090.44 MB
- Revised 09/08/20090.35 MB
- Revised 06/07/20090.44 MB
- Revised 16/08/20080.35 MB
- Revised 05/05/20080.34 MB
- Revised 20/01/20080.35 MB
- Revised 21/08/20070.33 MB
- Revised 16/05/20070.33 MB
- Revised 12/02/20070.33 MB
- Revised 21/01/20070.34 MB
- Revised 08/04/20060.37 MB
- Revised 19/11/20050.29 MB
- Revised 18/10/20050.29 MB
- Revised 14/09/20050.29 MB
- Revised 11/07/20050.29 MB
- Revised 20/03/20050.29 MB
- Revised 22/02/20050.28 MB
- Revised 28/12/20040.28 MB
- Revised 16/08/20030.27 MB
- Revised 28/06/20030.27 MB
- Revised 11/06/20030.27 MB
- Revised 05/06/20030.27 MB
- Revised 27/05/20030.27 MB
- Revised 17/03/20030.27 MB
- Revised 30/12/20020.27 MB
- Revised 01/12/20020.26 MB
- Revised 27/10/20020.26 MB
- Revised 31/08/20020.26 MB
- Revised 24/07/20020.26 MB
- Revised 19/03/20020.26 MB
- Revised 27/02/20020.25 MB
- Revised 07/01/20020.25 MB
- Revised 26/11/20010.25 MB
- Revised 14/11/20010.25 MB
- Revised 22/10/20010.25 MB
- Revised 29/09/20010.25 MB
- Revised 17/09/20010.25 MB
- Revised 28/08/20010.25 MB
- Revised 27/08/20010.25 MB
- Revised 26/06/20010.25 MB
- Revised 18/06/20010.24 MB
- Revised 28/02/20010.24 MB
- Revised 17/01/20010.23 MB
- Revised 27/12/20000.23 MB
- Revised 20/12/20000.23 MB
- Revised 15/11/20000.23 MB
- Revised 20/08/20000.22 MB
- Revised 19/08/20000.22 MB
- Revised 21/02/20000.22 MB
- Revised 20/02/20000.21 MB
- Revised 07/02/20000.20 MB
- Revised 11/01/20000.19 MB
- Revised 10/01/20000.19 MB
- Revised 10/11/19990.19 MB
- Revised 09/11/19990.18 MB
- Revised 11/07/19990.17 MB
- Revised 05/07/19990.16 MB
- Revised 26/06/19990.16 MB
- Revised 16/06/19990.16 MB
- Revised 08/05/19990.15 MB
- Revised 18/05/19920.06 MB
Legislation originating from the EU
When the UK left the EU, legislation.gov.uk published EU legislation that had been published by the EU up to IP completion day (31 December 2020 11.00 p.m.). On legislation.gov.uk, these items of legislation are kept up-to-date with any amendments made by the UK since then.
This item of legislation originated from the EU
Legislation.gov.uk publishes the UK version. EUR-Lex publishes the EU version. The EU Exit Web Archive holds a snapshot of EUR-Lex’s version from IP completion day (31 December 2020 11.00 p.m.).
Changes over time for: Division 2.
Version Superseded: 08/04/2006
Alternative versions:
- 28/12/2004- Amendment
- 22/02/2005- Amendment
- 20/03/2005- Amendment
- 11/07/2005- Amendment
- 14/09/2005- Amendment
- 18/10/2005- Amendment
- 18/10/2005
Point in time - 08/04/2006- Amendment
- 21/01/2007- Amendment
- 12/02/2007- Amendment
- 20/01/2008- Amendment
- 16/08/2008- Amendment
- 06/07/2009- Amendment
- 09/08/2009- Amendment
- 02/09/2009- Amendment
- Exit day: start of implementation period31/01/2020 11pm- Amendment
- End of implementation period31/12/2020- Amendment
Status:
Point in time view as at 18/10/2005.
Changes to legislation:
There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), Division
2.
.
Changes to Legislation
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
[F12. Antiparasitic agents U.K.
2.1. Agents acting against endoparasites U.K.
2.1.1. Salicylanilides U.K.
| Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
|---|---|---|---|---|---|
| Closantel | Closantel | Bovine | 1 000 μg/kg | Muscle | |
| 3 000 μg/kg | Fat | ||||
| 1 000 μg/kg | Liver | ||||
| 3 000 μg/kg | Kidney | ||||
| Ovine | 1 500 μg/kg | Muscle | |||
| 2 000 μg/kg | Fat | ||||
| 1 500 μg/kg | Liver | ||||
| 5 000 μg/kg | Kidney | ||||
| [F2Rafoxanide | Rafoxanide | Bovine | 30 μg/kg | Muscle | Not for use in animals from which milk is produced for human consumption |
| 30 μg/kg | Fat | ||||
| 10 μg/kg | Liver | ||||
| 40 μg/kg | Kidney | ||||
| Ovine | 100 μg/kg | Muscle | |||
| 250 μg/kg | Fat | ||||
| 150 μg/kg | Liver | ||||
| 150 μg/kg | Kidney] |
Textual Amendments
F2 Inserted by Commission Regulation (EC) No 1478/2001 of 18 July 2001 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
2.1.2. Tatra-hydro-imidazoles (imidazolthiazoles) U.K.
| Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
|---|---|---|---|---|---|
| Levamisole | Levamisole | Bovine, ovine, porcine, poultry | 10 μg/kg | Muscle | |
| 10 μg/kg | Fat | ||||
| 100 μg/kg | Liver | ||||
| 10 μg/kg | Kidney |
2.1.3. Benzimidazoles and pro-benzimidazoles U.K.
| Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
|---|---|---|---|---|---|
| [F3Albendazole | Sum of albendazole sulphoxide, albendazole sulphone, and albendazole 2-amino sulphone, expressed as albendazole | All ruminants | 100 μg/kg | Muscle | |
| 100 μg/kg | Fat | ||||
| 1 000 μg/kg | Liver | ||||
| 500 μg/kg | Kidney | ||||
| 100 μg/kg | Milk] | ||||
| [F4Albendazole oxide | Sum of albendazole oxide, albendazole sulphone and albendazole 2-aminosulphone, expressed as albendazole | Bovine, ovine | 100 μg/kg | Muscle | |
| 100 μg/kg | Fat | ||||
| 1 000 μg/kg | Liver | ||||
| 500 μg/kg | Kidney | ||||
| 100 μg/kg | Milk | ] | |||
| [F3Febantel | Sum of extractable residues which may be oxidised to oxfendazole sulphone | All ruminants | 50 μg/kg | Muscle | |
| 50 μg/kg | Fat | ||||
| 500 μg/kg | Liver | ||||
| 50 μg/kg | Kidney | ||||
| 10 μg/kg | Milk | ||||
| Fenbendazole | Sum of extractable residues which may be oxidised to oxfendazole sulphone | All ruminants | 50 μg/kg | Muscle | |
| 50 μg/kg | Fat | ||||
| 500 μg/kg | Liver | ||||
| 50 μg/kg | Kidney | ||||
| 10 μg/kg | Milk] | ||||
| Flubendazole | Sum of flubendazole and (2-amino 1H-benzimidazol-5-yl) (4fluorophenyl) methanone | Porcine, chicken, game birds | 50 μg/kg | Muscle | |
| 50 μg/kg | Skin and fat | ||||
| 400 μg/kg | Liver | ||||
| 300 μg/kg | Kidney | ||||
| [F5 | Turkey | 50 μg/kg | Muscle | ||
| 50 μg/kg | Skin and fat | ||||
| 400 μg/kg | Liver | ||||
| 300 μg/kg | Kidney | ] | |||
| Flubendazole | Chicken | 400 μg/kg | Eggs | ||
| [F6Mebendazole | Sum of mebendazole methyl (5-(1-hydroxy, 1-phenyl) methyl-1H-benzimidazol-2-yl) carbamate and (2-amino-1H-benzimidazol-5-yl) phenylmethanone, expressed as mebendazole equivalents | Ovine, caprine, equidae | 60 μg/kg | Muscle | Not for use in animals from which milk is produced for human consumption |
| 60 μg/kg | Fat | ||||
| 400 μg/kg | Liver | ||||
| 60 μg/kg | Kidney] | ||||
| [F7Netobimin | Sum of albendazole oxide, albendazole sulphone and albendazole 2-aminosulphone, expressed as albendazole | [X1Bovine, ovine] | 100 μg/kg | Muscle | For oral use only |
| 100 μg/kg | Fat | ||||
| 1 000 μg/kg | Liver | ||||
| 500 μg/kg | Kidney | ||||
| 100 μg/kg | Milk] | ||||
| [F3Oxfendazole | Sum of extractable residues which may be oxidised to oxfendazole sulphone | All ruminants | 50 μg/kg | Muscle | |
| 50 μg/kg | Fat | ||||
| 500 μg/kg | Liver | ||||
| 50 μg/kg | Kidney | ||||
| 10 μg/kg | Milk] | ||||
| Oxibendazole | Oxibendazole | Porcine | 100 μg/kg | Muscle | |
| 500 μg/kg | Skin and fat | ||||
| 200 μg/kg | Liver | ||||
| 100 μg/kg | Kidney | ||||
| [F3Thiabendazole | Sum of thiabendazole and 5-hydroxythiabendazole | Caprine | 100 μg/kg | Muscle | |
| 100 μg/kg | Fat | ||||
| 100 μg/kg | Liver | ||||
| 100 μg/kg | Kidney | ||||
| 100 μg/kg | Milk] | ||||
| Triclabendazole | Sum of extractable residues that may be oxidised to ketotriclabendazole | Bovine, ovine | 100 μg/kg | Muscle | Not for use in animals from which milk is produced for human consumption |
| 100 μg/kg | Liver | ||||
| 100 μg/kg | Kidney |
Editorial Information
X1 Substituted by Corrigendum to Commission Regulation (EC) No 807/2001 of 25 April 2001 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Official Journal of the European Communities L 118 of 27 April 2001).
Textual Amendments
F3 Substituted by Commission Regulation (EC) No 1646/2004 of 20 September 2004 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F4 Inserted by Commission Regulation (EC) No 2393/1999 of 11 November 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F5 Inserted by Commission Regulation (EC) No 2385/1999 of 10 November 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F6 Inserted by Commission Regulation (EC) No 1680/2001 of 22 August 2001 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F7 Inserted by Commission Regulation (EC) No 807/2001 of 25 April 2001 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
[F82.1.4. Phenol derivatives including salicylanides U.K.
| Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
|---|---|---|---|---|---|
| Nitroxinil | Nitroxinil | Bovine, ovine | 400 μg/kg | Muscle | |
| 200 μg/kg | Fat | ||||
| 20 μg/kg | Liver | ||||
| 400 μg/kg | Kidney | ||||
| [F3Oxyclozanide | Oxyclozanide | All ruminants | 20 μg/kg | Muscle | |
| 20 μg/kg | Fat | ||||
| 500 μg/kg | Liver | ||||
| 100 μg/kg | Kidney | ||||
| 10 μg/kg | Milk] ] |
Textual Amendments
F8 Inserted by Commission Regulation (EC) No 997/1999 of 11 May 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
[F92.1.5. Benzenesulphonamides U.K.
| Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
|---|---|---|---|---|---|
| Clorsulon | Clorsulon | Bovine | 35 μg/kg | Muscle | |
| 100 μg/kg | Liver | ||||
| 200 μg/kg | Kidney | ] |
Textual Amendments
F9 Inserted by Commission Regulation (EC) No 1942/1999 of 10 September 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
[F102.1.6. Piperazine derivatives U.K.
| Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
|---|---|---|---|---|---|
| Piperazine | Piperazine | Porcine | 400 μg/kg | Muscle | |
| 800 μg/kg | Skind and fat | ||||
| 2 000 μg/kg | Liver | ||||
| 1 000 μg/kg | Kidney | ||||
| Chicken | 2 000 μg/kg | Eggs | ] |
Textual Amendments
F10 Inserted by Commission Regulation (EC) No 868/2002 of 24 May 2002 amending Annexes I and II of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
[F112.1.7. Tetrahydropyrimides U.K.
| Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
|---|---|---|---|---|---|
| Morantel | Sum of residues which may be hydrolysed to N-methyl-1,3- propanediamine and expressed as morantel equivalents | Bovine, ovine | 100 μg/kg | Muscle | |
| 100 μg/kg | Fat | ||||
| 800 μg/kg | Liver | ||||
| 200 μg/kg | Kidney | ||||
| 50 μg/kg | Milk | ||||
| [F12All ruminants | 100 μg/kg | Muscle | |||
| 100 μg/kg | Fat | ||||
| 800 μg/kg | Liver | ||||
| 200 μg/kg | Kidney | ||||
| 50 μg/kg | Milk | ] ] |
Textual Amendments
F12 Inserted by Commission Regulation (EC) No 1356/2005 of 18 August 2005 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards oxolinic acid and morantel (Text with EEA relevance).
Textual Amendments
F11 Inserted by Commission Regulation (EC) No 1851/2004 of 25 October 2004 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits for veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
2.2. Agents acting against ectoparasites U.K.
2.2.1. Organophosphates U.K.
| Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
|---|---|---|---|---|---|
| [F2Coumafos | Coumafos | Bees | 100 μg/kg | Honey | ] |
| Diazinon | Diazinon | Bovine, ovine, caprine | 20 μg/kg | Milk | |
| Bovine, porcine, ovine, caprine | 20 μg/kg | Muscle | |||
| 700 μg/kg | Fat | ||||
| 20 μg/kg | Liver | ||||
| 20 μg/kg | Kidney | ||||
| [F7Phoxim | Phoxim | Ovine | 50 μg/kg | Muscle | Not for use in animals from which milk is produced for human consumption |
| 400 μg/kg | Fat | ||||
| 50 μg/kg | Kidney | ||||
| Porcine | 20 μg/kg | Muscle | |||
| 700 μg/kg | Skin and fat | ||||
| 20 μg/kg | Liver | ||||
| 20 μg/kg | Kidney | ||||
| [F13Chicken | 25 μg/kg | Muscle | |||
| 550 μg/kg | Skin + fat | ||||
| 50 μg/kg | Liver | ||||
| 30 μg/kg | Kidney | ||||
| 60 μg/kg | Eggs | ] ] |
Textual Amendments
F13 Inserted by Commission Regulation (EC) No 1299/2005 of 8 August 2005 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards phenoxymethylpenicillin, phoxim, norgestomet and thiamphenicol (Text with EEA relevance).
2.2.2. Formamidines U.K.
| Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
|---|---|---|---|---|---|
| Amitraz | Sum of amitraz and all metabolites containing the 2,4-DMA moiety, expressed as amitraz | Bovine | 200 μg/kg | Fat | |
| 200 μg/kg | Liver | ||||
| 200 μg/kg | Kidney | ||||
| 10 μg/kg | Milk | ||||
| Ovine | 400 μg/kg | Fat | |||
| 100 μg/kg | Liver | ||||
| 200 μg/kg | Kidney | ||||
| 10 μg/kg | Milk | ||||
| Porcine | 400 μg/kg | Skin and fat | |||
| 200 μg/kg | Liver | ||||
| 200 μg/kg | Kidney | ||||
| [F4 | Bees (honey) | 200 μg/kg | Honey | ] | |
| [F14 | Caprine | 200 μg/kg | Fat | ||
| 100 μg/kg | Liver | ||||
| 200 μg/kg | Kidney | ||||
| 10 μg/kg | Milk | ] |
Textual Amendments
F14 Inserted by Commission Regulation (EC) No 1646/2004 of 20 September 2004 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
2.2.3. Pyrethroids U.K.
| a [F15Further provisions in Commission Directive 98/82/EC are to be observed ( OJ L 290, 29.10.1998, p. 25 ).] | |||||
| Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
|---|---|---|---|---|---|
| [F7 [X1Cyhalothrin | Cyhalothrin (sum of isomers) | Bovine | 500 μg/kg | Fat | Further provisions in Council Directive 94/29/EC are to be observed |
| 50 μg/kg | Kidney | ||||
| 50 μg/kg | Milk | ||||
| Cyfluthrin | Cyfluthrin (sum of isomers) | Bovine | 10 μg/kg | Muscle | |
| 50 μg/kg | Fat | ||||
| 10 μg/kg | Liver | ||||
| 10 μg/kg | Kidney | ||||
| 20 μg/kg | Milk] ] | ||||
| [F16 [F3Deltamethrin | Deltamethrin | All ruminants | 10 μg/kg | Muscle | |
| 50 μg/kg | Fat | ||||
| 10 μg/kg | Liver | ||||
| 10 μg/kg | Kidney | ||||
| 20 μg/kg | Milk] | ||||
| [F17Fin fish | 10 μg/kg | Muscle and skin in natural proportions] ] | |||
| Flumethrin | Flumethrin (sum of trans-Z isomers) | Bovine | 10 μg/kg | Muscle | |
| 150 μg/kg | Fat | ||||
| 20 μg/kg | Liver | ||||
| 10 μg/kg | Kidney | ||||
| 30 μg/kg | Milk | ||||
| [F18 | Ovine | 10 μg/kg | Muscle | Not for use in animals from which milk is produced for human consumption | |
| 150 μg/kg | Fat | ||||
| 20 μg/kg | Liver | ||||
| 10 μg/kg | Kidney | ] | |||
| [F15Permethrin | Permethrin (sum of isomers) | Bovine | 50 μg/kg | Muscle | |
| 500 μg/kg | Fat | ||||
| 50 μg/kg | Liver | ||||
| 50 μg/kg | Kidney | ||||
| 50 μg/kg | Milk a | ] | |||
| [F19Cypermethrin | Cypermethrin (sum of isomers) | Salmonidae | 50 μg/kg | Muscle and skin in natural proportions | ] |
| [F3All ruminants | 20 μg/kg | Muscle | |||
| 200 μg/kg | Fat | ||||
| 20 μg/kg | Liver | ||||
| 20 μg/kg | Kidney | ||||
| 20 μg/kg | Milk a | ] | |||
| [F20Alphacypermethrin | Cypermethrin (sum of isomers) | Bovine, ovine | 20 μg/kg | Muscle | |
| 200 μg/kg | Fat | ||||
| 20 μg/kg | Liver | ||||
| 20 μg/kg | Kidney | ||||
| 20 μg/kg | Milk] a | ||||
Textual Amendments
F15 Inserted by Commission Regulation (EC) No 61/2003 of 15 January 2003 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F16 Inserted by Commission Regulation (EC) No 1815/2001 of 14 September 2001 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F17 Inserted by Commission Regulation (EC) No 2162/2001 of 7 November 2001 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F18 Inserted by Commission Regulation (EC) No 2391/2000 of 27 October 2000 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F19 Inserted by Commission Regulation (EC) No 1029/2003 of 16 June 2003 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F20 Inserted by Commission Regulation (EC) No 2011/2003 of 14 November 2003 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
[F212.2.4. Acyl urea derivatives U.K.
| Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
|---|---|---|---|---|---|
| [F22Diflubenzuron | Diflubenzuron | Salmonidae | 1 000 μg/kg | Muscle and skin in natural proportions | ] |
| Teflubenzuron | Teflubenzuron | Salmonidae | 500 μg/kg | Muscle and skin in natural proportions | ] |
Textual Amendments
F22 Inserted by Commission Regulation (EC) No 2593/1999 of 8 December 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
Textual Amendments
F21 Inserted by Commission Regulation (EC) No 1931/1999 of 9 September 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
[F232.2.5. Pyrimidines derivatives U.K.
| Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
|---|---|---|---|---|---|
| Dicyclanil | Sum of dicyclanil and 2, 4, 6-triamino-pyrimidine-5-carbonitrile | Ovine | 200 μg/kg | Muscle | Not for use in animals from which milk is produced for human consumption |
| [F24150 μg/kg] | Fat | ||||
| 400 μg/kg | Liver | ||||
| 400 μg/kg | Kidney] |
Textual Amendments
F24 Substituted by Commission Regulation (EC) No 2391/2000 of 27 October 2000 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
Textual Amendments
F23 Inserted by Commission Regulation (EC) No 1960/2000 of 15 September 2000 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
[F22.2.6. Triazine derivatives U.K.
| Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
|---|---|---|---|---|---|
| Cyromazine | Cyromazine | Ovine | 300 μg/kg | Muscle | Not for use in animals from which milk is produced for human consumption |
| 300 μg/kg | Fat | ||||
| 300 μg/kg | Liver | ||||
| 300 μg/kg | Kidney] |
2.3. Agents acting against endo- and ectoparasites U.K.
2.3.1. Avermectins U.K.
| a [F25Not for use in animals from which milk is produced for human consumption.] | |||||
| Phramacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
|---|---|---|---|---|---|
| Abamectin | Avermectin B1a | Bovine | 10 μg/kg | Fat | |
| 20 μg/kg | Liver | ||||
| [F10 | Ovine | 20 μg/kg | Muscle | Not for use in animals from which milk is produced for human consumption | |
| 50 μg/kg | Fat | ||||
| 25 μg/kg | Liver | ||||
| 20 μg/kg | Kidney | ] | |||
| Doramectin | Doramectin | Bovine | 10 μg/kg | Muscle | Not for use in bovine from which milk is produced for human consumption |
| 150 μg/kg | Fat | ||||
| 100 μg/kg | Liver | ||||
| 30 μg/kg | Kidney | ||||
| Porcine, ovine | 20 μg/kg | Muscle | Not for use in ovine from which milk is produced for human consumption | ||
| 100 μg/kg | Fat | ||||
| 50 μg/kg | Liver | ||||
| 30 μg/kg | Kidney | ||||
| [F2 | Deer, including reindeer | 20 μg/kg | Muscle | ||
| 100 μg/kg | Fat | ||||
| 50 μg/kg | Liver | ||||
| 30 μg/kg | Kidney | ] | |||
| [F26Emamectin | Emamectin B1a | Fin fish | 100 μg/kg | Muscle and skin in natural proportions | ] |
| Eprinomectin | Eprinomectin B1a | Bovine | [F2750 μg/kg] | Muscle | |
| [F27250 μg/kg] | Fat | ||||
| [F271 500 μg/kg] | Liver | ||||
| [F27300 μg/kg] | Kidney | ||||
| [F2720 μg/kg] | Milk | ||||
| Ivermectin | 22, 23-Dihydro-avermectin B1a | Bovine | 40 μg/kg | Fat | |
| 100 μg/kg | Liver | ||||
| Porcine, ovine, equidae | 20 μg/kg | Fat | |||
| 15 μg/kg | Liver | ||||
| Deer, including reindeer | 20 μg/kg | Muscle | |||
| 100 μg/kg | Fat | ||||
| 50 μg/kg | Liver | ||||
| 20 μg/kg | Kidney | ||||
| [F28 | All mammalian food-producing species a | 100 μg/kg | Fat | ||
| 100 μg/kg | Liver | ||||
| 30 μg/kg | Kidney | ] | |||
| Moxidectin | Moxidectin | Bovine, ovine | 50 μg/kg | Muscle | |
| 500 μg/kg | Fat | ||||
| 100 μg/kg | Liver | ||||
| 50 μg/kg | Kidney | ||||
| [F29 | Bovine | 40 μg/kg | Milk | ] | |
| [F9 | Equidae | 50 μg/kg | Muscle | ||
| 500 μg/kg | Fat | ||||
| 100 μg/kg | Liver | ||||
| 50 μg/kg | Kidney | ] | |||
| [F30 | Ovine | 40 μg/kg | Milk | ] | |
Textual Amendments
F25 Inserted by Commission Regulation (EC) No 869/2005 of 8 June 2005 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin as regards ivermectin and carprofen (Text with EEA relevance).
F26 Substituted by Commission Regulation (EC) No 1490/2003 of 25 August 2003 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F27 Substituted by Commission Regulation (EC) No 1943/1999 of 10 September 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F28 Substituted by Commission Regulation (EC) No 869/2005 of 8 June 2005 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin as regards ivermectin and carprofen (Text with EEA relevance).
F29 Inserted by Commission Regulation (EC) No 1553/2001 of 30 July 2001 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F30 Inserted by Commission Regulation (EC) No 75/2005 of 18 January 2005 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin as regards moxidectin, linear alkyl benzene sulphonic acids with alkyl chain lengths ranging from C9 to C13, containing less than 2,5 % of chains longer than C13 and Acetylisovaleryltylosin (Text with EEA relevance).
2.4. Agents acting against protozoa U.K.
2.4.1. Triazinetrione derivative U.K.
| Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
|---|---|---|---|---|---|
| Toltrazuril | Toltrazuril sulfone | Chicken | 100 μg/kg | Muscle | Not for use in animals from which eggs are produced for human consumption |
| 200 μg/kg | Skin and fat | ||||
| 600 μg/kg | Liver | ||||
| 400 μg/kg | Kidney | ||||
| Turkey | 100 μg/kg | Muscle | |||
| 200 μg/kg | Skin and fat | ||||
| 600 μg/kg | Liver | ||||
| 400 μg/kg | Kidney | ||||
| [F31 | Porcine | 100 μg/kg | Muscle | ||
| 150 μg/kg | Skin and fat | ||||
| 500 μg/kg | Liver | ||||
| 250 μg/kg | Kidney | ] |
Textual Amendments
F31 Inserted by Commission Regulation (EC) No 2908/2000 of 29 December 2000 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
[F312.4.2. Quinazolone derivatives U.K.
| Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
|---|---|---|---|---|---|
| Halofuginone | Halofuginone | Bovine | 10 μg/kg | Muscle | Not for use in animals from which milk is produced for human consumption |
| 25 μg/kg | Fat | ||||
| 30 μg/kg | Liver | ||||
| 30 μg/kg | Kidney] |
[F172.4.3. Carbanilides U.K.
| a [F32Not for use in ovine from which milk is produced for human consumption.] ] | |||||
| Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
|---|---|---|---|---|---|
| Imidocarb | Imidocarb | Bovine | 300 μg/kg | Muscle | |
| 50 μg/kg | Fat | ||||
| 2 000 μg/kg | Liver | ||||
| 1 500 μg/kg | Kidney | ||||
| 50 μg/kg | Milk | ||||
| [F32Ovine a | 300 μg/kg | Muscle | |||
| 50 μg/kg | Fat | ||||
| 2 000 μg/kg | Liver | ||||
| 1 500 μg/kg | Kidney | ] | |||
Textual Amendments
F32 Inserted by Commission Regulation (EC) No 2145/2003 of 8 December 2003 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
[F332.4.4. Ionophores U.K.
| a Not for use in animals from which eggs are produced for human consumption.] ] | |||||
| Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
|---|---|---|---|---|---|
| Lasalocid | Lasalocid A | Poultry a | 20 μg/kg | Muscle | |
| 100 μg/kg | Skin + fat | ||||
| 100 μg/kg | Liver | ||||
| 50 μg/kg | Kidney | ||||
Textual Amendments
F33 Inserted by Commission Regulation (EC) No 712/2005 of 11 May 2005 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin as regards lasalocid and ammonium and sodium salts of bituminosulfonates (Text with EEA relevance).
Textual Amendments
Options/Help
Print Options
PrintThe Whole Regulation
PrintThe Whole Annex
PrintThis Division only
Legislation is available in different versions:
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As adopted by EU): The original version of the legislation as it stood when it was first adopted in the EU. No changes have been applied to the text.
Point in Time: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.
See additional information alongside the content
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Opening Options
Different options to open legislation in order to view more content on screen at once
More Resources
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
- the original print PDF of the as adopted version that was used for the EU Official Journal
- lists of changes made by and/or affecting this legislation item
- all formats of all associated documents
- correction slips
- links to related legislation and further information resources
Timeline of Changes
This timeline shows the different versions taken from EUR-Lex before exit day and during the implementation period as well as any subsequent versions created after the implementation period as a result of changes made by UK legislation.
The dates for the EU versions are taken from the document dates on EUR-Lex and may not always coincide with when the changes came into force for the document.
For any versions created after the implementation period as a result of changes made by UK legislation the date will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. For further information see our guide to revised legislation on Understanding Legislation.
More Resources
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
- the original print PDF of the as adopted version that was used for the print copy
- correction slips
Click 'View More' or select 'More Resources' tab for additional information including:
- lists of changes made by and/or affecting this legislation item
- confers power and blanket amendment details
- all formats of all associated documents
- links to related legislation and further information resources
All content is available under the Open Government Licence v3.0 except where otherwise stated. This site additionally contains content derived from EUR-Lex, reused under the terms of the Commission Decision 2011/833/EU on the reuse of documents from the EU institutions. For more information see the EUR-Lex public statement on re-use.